---
freshness:
  last-reviewed: 2026-02-05
  data-year: 2025
  review-cycle: 12
  sections:
    - name: "Legislation Evaluations"
      data-year: 2025
    - name: "Engagement Consistency Assessment"
      data-year: 2025
notes:
  - Revisit after FY2026 NIH appropriations votes to update legislation status.
  - Flag any new oversight hearings or structural reform proposals for reassessment.
  - Update after 2026 midterms to reflect any changed party positions on science funding.
sources:
  count: 14
  verified: 2026-02-05
  broken: 0
---

# Biomedical Research: Political Perspectives Analysis

## Overview

This document analyzes biomedical research reform through nine distinct political perspectives, evaluating current state assessments, root cause analyses, proposed solutions, and legislation. Each perspective receives engagement-consistency ratings and position scores, culminating in compromise proposals that bridge multiple viewpoints. Biomedical research is a relatively bipartisan policy area, with most perspectives supporting increased NIH funding in principle but diverging significantly on structural reform, workforce policy, and the government's role in drug development and pricing.

## Perspective Definitions

| Perspective | Core Values | Policy Orientation |
|-------------|-------------|-------------------|
| Conservative | Tradition, limited government, individual responsibility | Incremental change, fiscal restraint, market solutions |
| Liberal | Progress, equality, social responsibility | Government as problem-solver, regulation, safety nets |
| Progressive | Systemic change, economic justice, structural reform | Transformative reform, wealth redistribution, worker power |
| Libertarian | Individual liberty, minimal state, free markets | Deregulation, privatization, voluntary association |
| Constitutionalist | Original intent, enumerated powers, federalism | Strict constitutional limits, states' rights |
| Populist | Anti-elite, pro-worker, economic nationalism | Trade protection, anti-monopoly, immigration restriction |
| Centrist | Pragmatism, compromise, incremental progress | Bipartisan solutions, evidence-based policy |
| Religious Right | Faith-based values, traditional morality | Social conservatism, religious liberty |
| Democratic Socialist | Worker ownership, public goods, democratic control | Public investment, labor rights, universal programs |

## Scoring Framework

### Position Scores (1-10)

| Score | Meaning |
|-------|---------|
| 10 | Full agreement with project analysis |
| 7-9 | Substantial to strong agreement |
| 5-6 | Mixed/moderate agreement |
| 3-4 | Substantial disagreement |
| 1-2 | Strong opposition |

### Engagement Consistency (1-5)

| Level | Label | Indicators |
|-------|-------|------------|
| 5 | Highly Consistent | Stated motivations = actual motivations; consistent principles across contexts |
| 4 | Mostly Consistent | Genuine beliefs with minor strategic exceptions |
| 3 | Mixed Consistency | Some genuine concerns combined with some strategic positioning |
| 2 | Low Consistency | Pretextual objections; goalposts move; selective principle application |
| 1 | Unpredictable | Pure obstruction; zero-sum warfare; oppose because opponents support |

**Coalition-Building Considerations:**

- Alignment gap: When stated concerns differ from underlying priorities, addressing stated concerns may not secure support
- Position stability: Perspectives with shifting positions require ongoing negotiation
- Principle consistency: Perspectives that apply principles uniformly are more predictable partners
- Internal diversity: Some perspectives contain factions with different priorities

### Legislation Status Reference (as of February 2026)

| Bill/Amendment | Type | Current Status | Last Action |
|----------------|------|----------------|-------------|
| NIH Reform and Accountability Act | Federal Legislation | Proposed | Not yet introduced in Congress |
| Clinical Trial Modernization Act | Federal Legislation | Proposed | Not yet introduced in Congress |

*Note: Status reflects 119th Congress (2025-2026). See [11-legislation.md](11-legislation.md) for full bill text.*

---

## Perspective Analyses

### Conservative Perspective

#### Engagement Consistency Assessment

**Score: 4/5 - Mostly Consistent**

| Indicator | Assessment |
|-----------|------------|
| Stated vs actual motivations | Genuine fiscal concerns about spending and government overreach; generally honest about priorities |
| Principle consistency | Support for NIH funding broadly consistent with national competitiveness framing; some tension with small-government principles |
| Goalpost stability | Stable positions on funding levels and accountability; consistent F&A reform interest |
| Zero-sum behavior | Low; biomedical research is not a partisan battlefield for most conservatives |

**Justification:** Conservatives have historically supported NIH funding as a matter of national competitiveness and economic growth. Opposition tends to be principled (fiscal discipline, government scope) rather than strategic. The main inconsistency arises when fiscal discipline arguments are applied selectively -- supporting defense spending increases while questioning NIH growth.

**Evidence for assessment:**

- Bipartisan support for the 21st Century Cures Act (2016), with strong Republican backing
- Republican senators (Specter, Collins) were key champions of the NIH doubling
- Heritage Foundation has published analyses supporting targeted biomedical research investment while opposing open-ended spending growth

#### Position Scores

| Dimension | Score | Reasoning |
|-----------|-------|-----------|
| Current State Assessment | 7/10 | *Agree with analysis of funding inefficiency, reproducibility problems, and administrative burden; less agreement on workforce characterization as "exploitation"* |
| Root Cause Agreement | 6/10 | *Agree that government bureaucracy and perverse incentives are problems; disagree that the solution is more government intervention; attribute industry retreat to regulation rather than market failure* |

**Source references:**

- American Enterprise Institute reports on research productivity and NIH management
- Heritage Foundation, "Federal Research Spending: Targeting Innovation" (2023)

#### Solution Evaluations

| Solution | Score | Stated Position | Underlying Concerns |
|----------|-------|-----------------|---------------------|
| Longer, larger grants | 7/10 | *Support reducing bureaucratic burden on researchers* | *Efficiency gains align with fiscal conservatism* |
| F&A cost reform | 8/10 | *Strong support for transparency and accountability in spending* | *Genuine concern about waste; also opportunity to reduce spending* |
| Diversifying funding portfolio | 5/10 | *Cautious about mandated redistribution; prefer merit-based allocation* | *Concern that set-asides compromise quality* |
| Clinical trial modernization | 8/10 | *Strong support for reducing regulatory burden and accelerating development* | *Aligns with deregulatory instincts* |
| Reproducibility mandates | 6/10 | *Support accountability in principle but wary of additional mandates* | *Tension between accountability and regulatory burden* |
| Workforce reform | 4/10 | *Market should determine wages and career paths; oppose mandated minimums* | *Ideological opposition to government wage-setting* |

#### Legislation Evaluations

| Bill | Score | Stated Position | Underlying Concerns |
|------|-------|-----------------|---------------------|
| NIH Reform and Accountability Act | 6/10 | *Support accountability and F&A reform; concerned about new spending authorizations and wage mandates* | *Would support a version focused on accountability without the spending increases and compensation mandates* |
| Clinical Trial Modernization Act | 7/10 | *Support deregulation and decentralization; cautious about diversity mandates and new spending* | *Prefer industry-led modernization with FDA regulatory relief* |

#### Alternative Proposals

- Focus on deregulation and FDA streamlining rather than new government programs
- Increase private sector incentives (tax credits for R&D) rather than direct federal spending
- Voluntary F&A transparency rather than mandatory caps
- Market-based approaches to workforce problems (let supply and demand adjust)
- Expand NIH-industry partnerships rather than government-directed translational programs

#### Coalition Potential

- **Natural allies:** Centrist, Libertarian (on deregulation and efficiency)
- **Potential bridges:** Liberal (on NIH funding), Populist (on accountability and transparency)
- **Unlikely partners:** Democratic Socialist (on pricing and government role), Progressive (on workforce mandates)

---

### Liberal Perspective

#### Engagement Consistency Assessment

**Score: 4/5 - Mostly Consistent**

| Indicator | Assessment |
|-----------|------------|
| Stated vs actual motivations | Genuine commitment to public health, equity, and scientific progress; some institutional loyalty to university system |
| Principle consistency | Consistently support government investment in research and social equity provisions |
| Goalpost stability | Stable support for increased funding, equity measures, and patient access |
| Zero-sum behavior | Low on research funding; moderate on drug pricing where industry opposition is intense |

**Justification:** Liberals have been the most consistent advocates for increased NIH funding and research workforce equity. Their positions on research reform are well-aligned with their broader commitments to government investment, equity, and public health. Minor inconsistencies arise around university interests -- liberal legislators from states with major research universities may resist F&A reform.

**Evidence for assessment:**

- Democratic leadership consistently proposes NIH budget increases
- Obama-era Precision Medicine Initiative and Biden Cancer Moonshot demonstrate commitment
- Strong support for the DEPICT Act and other diversity provisions
- Center for American Progress reports advocating for comprehensive research reform

#### Position Scores

| Dimension | Score | Reasoning |
|-----------|-------|-----------|
| Current State Assessment | 9/10 | *Strong agreement with analysis of funding challenges, diversity gaps, workforce problems, and translational failures* |
| Root Cause Agreement | 8/10 | *Agree with structural analysis of incentive problems; emphasize systemic inequality and corporate behavior as root causes* |

**Source references:**

- Center for American Progress, "Investing in Research for the Public Good" (2024)
- Congressional Progressive Caucus budget proposals for NIH funding
- Democratic party platform endorsements of science investment

#### Solution Evaluations

| Solution | Score | Stated Position | Underlying Concerns |
|----------|-------|-----------------|---------------------|
| Longer, larger grants | 8/10 | *Support reduced burden and stability for researchers* | *Want to ensure equity provisions are included* |
| F&A cost reform | 6/10 | *Support transparency; cautious about caps that could harm universities* | *Concern about impact on research institutions in their states* |
| Diversifying funding portfolio | 9/10 | *Strong support for equity provisions and early-career set-asides* | *Genuine commitment to diversity and inclusion* |
| Clinical trial modernization | 8/10 | *Strong support, especially for diversity and access provisions* | *Want robust patient protections alongside modernization* |
| Reproducibility mandates | 8/10 | *Support scientific rigor and transparency* | *Align with evidence-based governance philosophy* |
| Workforce reform | 9/10 | *Strong support for higher pay, benefits, and career transparency* | *Consistent with labor rights and worker protection values* |

#### Legislation Evaluations

| Bill | Score | Stated Position | Underlying Concerns |
|------|-------|-----------------|---------------------|
| NIH Reform and Accountability Act | 8/10 | *Strong support for most provisions; some concern about F&A cap impact on universities* | *Would strengthen diversity provisions and add drug pricing conditions* |
| Clinical Trial Modernization Act | 9/10 | *Enthusiastic support for diversity requirements, patient access, and community trial network* | *Want to ensure robust enforcement of diversity mandates* |

#### Alternative Proposals

- Add drug pricing conditions (reasonable pricing for publicly funded discoveries)
- Strengthen diversity mandates with binding enrollment targets
- Expand NIH budget to $60 billion with sustained annual growth
- Create a public pharmaceutical manufacturing facility for neglected diseases
- Expand Pell Grant-style support for graduate students

#### Coalition Potential

- **Natural allies:** Progressive, Democratic Socialist (on funding and equity)
- **Potential bridges:** Centrist (on evidence-based reform), Conservative (on NIH funding)
- **Unlikely partners:** Libertarian (on government role), Constitutionalist (on federal authority)

---

### Progressive Perspective

#### Engagement Consistency Assessment

**Score: 5/5 - Highly Consistent**

| Indicator | Assessment |
|-----------|------------|
| Stated vs actual motivations | Principles consistently applied: public investment, worker rights, equity, accountability |
| Principle consistency | Same framework applied across all policy areas; no selective application |
| Goalpost stability | Positions stable and clearly articulated; willing to accept partial wins without abandoning goals |
| Zero-sum behavior | Low; focused on expanding the pie rather than zero-sum competition |

**Justification:** Progressives apply a consistent structural analysis to biomedical research: public investment creates public goods that should benefit everyone, not just corporations and elite institutions. Their positions on workforce reform, drug pricing, and equity follow directly from core principles and are applied uniformly.

**Evidence for assessment:**

- Bernie Sanders and Elizabeth Warren's consistent advocacy for NIH reform with pricing conditions
- Progressive caucus budget proposals consistently prioritize research funding with equity provisions
- Academic economists aligned with progressive movement (Mazzucato, Stiglitz) provide intellectual framework

#### Position Scores

| Dimension | Score | Reasoning |
|-----------|-------|-----------|
| Current State Assessment | 9/10 | *Strong agreement; would emphasize even more the corporate capture of publicly funded research and exploitation of the workforce* |
| Root Cause Agreement | 9/10 | *Strong agreement with structural analysis; would add corporate power and financialization as additional root causes* |

**Source references:**

- Mazzucato, Mariana. *The Entrepreneurial State*. 2013. (Influential framework for progressive science policy)
- Sanders, Bernie. Congressional testimony on NIH reform and drug pricing
- Roosevelt Institute reports on public research and pharmaceutical pricing

#### Solution Evaluations

| Solution | Score | Stated Position | Underlying Concerns |
|----------|-------|-----------------|---------------------|
| Longer, larger grants | 7/10 | *Support, but want to ensure funding goes to diverse investigators, not just established elites* | *Concern about reproducing existing inequalities* |
| F&A cost reform | 9/10 | *Strong support for caps and transparency; universities should not profit from public research* | *View high F&A as administrative bloat benefiting administrators over researchers* |
| Diversifying funding portfolio | 10/10 | *Core priority; mandatory redistribution to early-career and underrepresented investigators* | *Genuine commitment to structural equity* |
| Clinical trial modernization | 8/10 | *Support access and diversity provisions; cautious about industry-friendly deregulation* | *Want to ensure modernization serves patients, not just industry efficiency* |
| Reproducibility mandates | 8/10 | *Support transparency and accountability in public spending* | *Consistent with good governance principles* |
| Workforce reform | 10/10 | *Central priority; trainees are exploited workers who deserve living wages and career security* | *Consistent with labor rights framework* |

#### Legislation Evaluations

| Bill | Score | Stated Position | Underlying Concerns |
|------|-------|-----------------|---------------------|
| NIH Reform and Accountability Act | 7/10 | *Support core provisions but want stronger F&A caps, mandatory pricing conditions, and binding diversity targets* | *Bill does not go far enough on pricing and equity* |
| Clinical Trial Modernization Act | 7/10 | *Support diversity and access provisions; want stronger enforcement and pricing conditions for resulting drugs* | *Concerned that industry will capture benefits without public return* |

#### Alternative Proposals

- Mandatory reasonable pricing for all drugs developed with significant NIH funding
- Exercise Bayh-Dole march-in rights for unaffordable publicly funded drugs
- Create a public pharmaceutical development corporation
- Mandatory union recognition for graduate students and postdocs on NIH funds
- Tie F&A cap at 30% (not 40%) with full transparency and independent audit
- Require open-access publication of all NIH-funded research immediately upon publication

#### Coalition Potential

- **Natural allies:** Democratic Socialist, Liberal (on funding, equity, workforce)
- **Potential bridges:** Populist (on accountability and anti-elite measures), Centrist (on evidence-based reform)
- **Unlikely partners:** Conservative (on pricing and workforce mandates), Libertarian (on government role)

---

### Libertarian Perspective

#### Engagement Consistency Assessment

**Score: 4/5 - Mostly Consistent**

| Indicator | Assessment |
|-----------|------------|
| Stated vs actual motivations | Genuine philosophical commitment to limited government and free markets |
| Principle consistency | Generally consistent: oppose government funding and regulation across domains |
| Goalpost stability | Stable positions on reducing government role; may pragmatically accept NIH existence |
| Zero-sum behavior | Low; principled opposition rather than strategic |

**Justification:** Libertarians consistently apply free-market principles to biomedical research, opposing government funding and regulation in favor of private investment and voluntary cooperation. The main tension is between pure ideology (abolish NIH) and pragmatic acceptance that government research funding produces substantial public goods that private markets would undersupply.

**Evidence for assessment:**

- Cato Institute publications consistently argue for reduced government role in research
- Reason Foundation analysis of NIH inefficiency and bureaucratic waste
- Libertarian think tanks have published critiques of the Bayh-Dole framework from a property rights perspective

#### Position Scores

| Dimension | Score | Reasoning |
|-----------|-------|-----------|
| Current State Assessment | 5/10 | *Agree that bureaucracy, inefficiency, and perverse incentives exist; disagree that the answer is more government intervention rather than less* |
| Root Cause Agreement | 4/10 | *Agree that government-created incentive structures are the problem; conclude the solution is removing government, not reforming it* |

**Source references:**

- Cato Institute, "The Case for Privatizing Scientific Research" (various)
- Reason Foundation analysis of NIH overhead and bureaucratic costs
- Mises Institute publications on government research funding

#### Solution Evaluations

| Solution | Score | Stated Position | Underlying Concerns |
|----------|-------|-----------------|---------------------|
| Longer, larger grants | 4/10 | *Marginal improvement but still government funding; prefer private alternatives* | *Ideological opposition to government grants* |
| F&A cost reform | 6/10 | *Support reducing waste but prefer eliminating the system rather than reforming it* | *Any government reform is insufficient; need market solutions* |
| Diversifying funding portfolio | 3/10 | *Oppose government-mandated redistribution; let merit and markets determine allocation* | *Mandated equity provisions violate free association and meritocracy* |
| Clinical trial modernization | 7/10 | *Support deregulation and removing barriers; oppose new government infrastructure* | *Favor FDA deregulation over new government programs* |
| Reproducibility mandates | 4/10 | *Market forces and journal competition should drive quality, not mandates* | *Oppose government regulation of scientific practice* |
| Workforce reform | 2/10 | *Government wage mandates distort labor markets; let supply and demand determine compensation* | *Fundamentally oppose government setting wages* |

#### Legislation Evaluations

| Bill | Score | Stated Position | Underlying Concerns |
|------|-------|-----------------|---------------------|
| NIH Reform and Accountability Act | 3/10 | *New authorizations and mandates are the wrong direction; support only the F&A transparency provisions* | *Would prefer a bill reducing NIH scope and funding* |
| Clinical Trial Modernization Act | 4/10 | *Support deregulatory elements but oppose new spending, diversity mandates, and government infrastructure* | *Prefer removing FDA barriers over building new government programs* |

#### Alternative Proposals

- Phase out NIH funding over 10-20 years, replacing with expanded tax incentives for private research
- Eliminate or dramatically reduce FDA authority over clinical trials
- Allow patients to access any treatment with informed consent (Right to Try expansion)
- Replace government grants with prize competitions for specific health challenges
- Privatize NIH intramural research programs

#### Coalition Potential

- **Natural allies:** Conservative (on deregulation and fiscal restraint)
- **Potential bridges:** Populist (on anti-establishment critique), Progressive (on open science)
- **Unlikely partners:** Liberal (on government role), Democratic Socialist (on public investment)

---

### Constitutionalist Perspective

#### Engagement Consistency Assessment

**Score: 4/5 - Mostly Consistent**

| Indicator | Assessment |
|-----------|------------|
| Stated vs actual motivations | Genuine belief in constitutional limits on federal power |
| Principle consistency | Generally consistent; some tension between strict construction and acceptance of longstanding federal programs |
| Goalpost stability | Stable positions based on constitutional text and precedent |
| Zero-sum behavior | Low; principled objections based on governmental structure |

**Justification:** Constitutionalists raise legitimate questions about the constitutional basis for federal biomedical research funding. While the General Welfare Clause and Commerce Clause have been broadly interpreted to support NIH, strict constructionists may argue that research funding should be a state responsibility. Their positions are principled but must contend with 80+ years of precedent and bipartisan acceptance of federal research funding.

**Evidence for assessment:**

- Federalist Society publications on the scope of the spending power
- Constitutional challenges to federal grant conditions (Sebelius, Dole)
- State-level research funding programs (California CIRM, Texas CPRIT) as models for constitutionalist approach

#### Position Scores

| Dimension | Score | Reasoning |
|-----------|-------|-----------|
| Current State Assessment | 5/10 | *Accept factual description but question whether federal involvement is the appropriate framework* |
| Root Cause Agreement | 4/10 | *Agree that centralized federal control creates problems; conclude that decentralization, not federal reform, is the answer* |

**Source references:**

- Federalist Society, "The Spending Power and Federal Research Grants" (various)
- State constitutionalist arguments for returning research authority to states
- Originalist scholarship on the General Welfare Clause

#### Solution Evaluations

| Solution | Score | Stated Position | Underlying Concerns |
|----------|-------|-----------------|---------------------|
| Longer, larger grants | 4/10 | *If NIH exists, this is reasonable, but prefer returning authority to states* | *Concerned about expanding federal role* |
| F&A cost reform | 5/10 | *Support limiting federal spending conditions but question federal authority to mandate institutional practices* | *Tension between accountability and federal overreach* |
| Diversifying funding portfolio | 3/10 | *Federal mandates on how to distribute funds overstep appropriate federal role* | *Prefer state-level decision-making* |
| Clinical trial modernization | 5/10 | *Support reducing federal regulation; cautious about creating new federal programs* | *FDA authority already exceeds constitutional bounds in their view* |
| Reproducibility mandates | 4/10 | *Federal mandates on research practice raise questions about enumerated powers* | *Prefer voluntary standards or state-level regulation* |
| Workforce reform | 3/10 | *Federal government should not set wages for university employees* | *Tenth Amendment reserves this to states and institutions* |

#### Legislation Evaluations

| Bill | Score | Stated Position | Underlying Concerns |
|------|-------|-----------------|---------------------|
| NIH Reform and Accountability Act | 3/10 | *Exceeds appropriate federal scope; prefer block grants to states for research funding* | *Constitutional concerns about conditions on spending* |
| Clinical Trial Modernization Act | 4/10 | *Support deregulatory elements; oppose new federal programs and mandates* | *Would prefer reducing FDA scope to creating new programs* |

#### Alternative Proposals

- Convert NIH to a block grant program distributing research funds to states
- Reduce FDA authority and allow states to establish their own drug approval pathways
- Sunset federal research programs and transfer authority to state governments
- Use Article V convention to clarify federal science policy authority

#### Coalition Potential

- **Natural allies:** Libertarian (on limited government), Conservative (on federalism)
- **Potential bridges:** Populist (on distrust of federal bureaucracy)
- **Unlikely partners:** Liberal, Progressive, Democratic Socialist (all favor strong federal role)

---

### Populist Perspective

#### Engagement Consistency Assessment

**Score: 3/5 - Mixed Consistency**

| Indicator | Assessment |
|-----------|------------|
| Stated vs actual motivations | Genuine anger at elite institutions and pharmaceutical companies; but positions sometimes shift based on political dynamics |
| Principle consistency | Anti-elite framing is consistent; but application varies -- sometimes supporting and sometimes opposing government intervention |
| Goalpost stability | Moderate; positions on NIH can shift depending on political context (e.g., COVID-era scrutiny vs. traditional support) |
| Zero-sum behavior | Moderate; tendency to frame research policy as elites vs. ordinary people |

**Justification:** Populists bring a valuable critique of how the research enterprise serves institutional interests over public benefit. Their concerns about pharmaceutical pricing, university overhead, and elite capture of funding are substantive. However, populist positions on biomedical research have become less predictable since the COVID-19 pandemic, when some populist figures became critical of NIH, gain-of-function research, and public health institutions more broadly.

**Evidence for assessment:**

- Pre-COVID bipartisan populist support for drug pricing reform (Trump and Sanders both campaigned on it)
- Post-COVID populist skepticism of NIH management and institutional science
- Populist support for accountability measures alongside distrust of scientific expertise

#### Position Scores

| Dimension | Score | Reasoning |
|-----------|-------|-----------|
| Current State Assessment | 7/10 | *Strong agreement that the system serves elites over ordinary people; emphasis on pharmaceutical profiteering and institutional waste* |
| Root Cause Agreement | 6/10 | *Agree that institutional incentives are corrupt; may attribute problems to individual bad actors rather than systemic structures* |

**Source references:**

- Bipartisan populist drug pricing proposals (both Trump-era and Sanders proposals)
- Populist critiques of university overhead and administrative bloat
- Post-COVID populist investigations into NIH and gain-of-function research

#### Solution Evaluations

| Solution | Score | Stated Position | Underlying Concerns |
|----------|-------|-----------------|---------------------|
| Longer, larger grants | 5/10 | *Neutral; not a priority for populist agenda* | *Does not address core populist concerns about accountability* |
| F&A cost reform | 9/10 | *Strong support; universities are wasting taxpayer money* | *Anti-elite framing resonates strongly* |
| Diversifying funding portfolio | 6/10 | *Support spreading funding beyond elite institutions; cautious about diversity mandates* | *Anti-elite aspect appeals; identity-based provisions less so* |
| Clinical trial modernization | 7/10 | *Support patient access and rural inclusion; suspicious of industry benefits* | *Want to ensure modernization helps ordinary people, not pharma profits* |
| Reproducibility mandates | 7/10 | *Support accountability for how taxpayer money is spent on research* | *Accountability framing resonates* |
| Workforce reform | 6/10 | *Support fair wages for workers; suspicious of academic elite framing* | *Worker-friendly aspects appeal; academic framing less so* |

#### Legislation Evaluations

| Bill | Score | Stated Position | Underlying Concerns |
|------|-------|-----------------|---------------------|
| NIH Reform and Accountability Act | 6/10 | *Support F&A reform and accountability; want drug pricing provisions; suspicious of new spending* | *Would add pharmaceutical pricing reform and tougher oversight of NIH leadership* |
| Clinical Trial Modernization Act | 6/10 | *Support patient access and rural provisions; cautious about new government programs* | *Want to ensure benefits reach ordinary Americans, not just pharmaceutical companies* |

#### Alternative Proposals

- Mandatory drug price caps for all treatments developed with NIH funding
- Congressional investigation and restructuring of NIH leadership
- Ban on NIH officials moving to pharmaceutical industry (cooling-off period)
- Direct-to-consumer drug importation from other countries
- Funding preferences for institutions outside the top 50 research universities

#### Coalition Potential

- **Natural allies:** Progressive (on drug pricing and anti-corporate measures)
- **Potential bridges:** Conservative (on accountability), Liberal (on funding access)
- **Unlikely partners:** Libertarian (on drug pricing regulation), Constitutionalist (on federal authority questions)

---

### Centrist Perspective

#### Engagement Consistency Assessment

**Score: 5/5 - Highly Consistent**

| Indicator | Assessment |
|-----------|------------|
| Stated vs actual motivations | Genuine commitment to evidence-based, pragmatic reform |
| Principle consistency | Consistently applies cost-benefit analysis and bipartisan feasibility criteria |
| Goalpost stability | Positions stable; willing to accept incremental progress |
| Zero-sum behavior | Very low; actively seeks compromise and bipartisan solutions |

**Justification:** Centrists are the most reliable reform partners on biomedical research because their positions are driven by evidence and pragmatism rather than ideology. They consistently support NIH funding, evidence-based reform, and bipartisan solutions. Their main limitation is a tendency toward incrementalism that may be insufficient to address structural problems.

**Evidence for assessment:**

- Bipartisan Policy Center reports on research policy emphasizing evidence and compromise
- Centrist senators (Collins, Shaheen, Cassidy) consistently support NIH funding increases
- 21st Century Cures Act as a model centrist achievement (bipartisan, evidence-based, pragmatic)

#### Position Scores

| Dimension | Score | Reasoning |
|-----------|-------|-----------|
| Current State Assessment | 8/10 | *Strong agreement with evidence-based analysis; may question some of the more structural critiques* |
| Root Cause Agreement | 7/10 | *Agree with most causal analysis; prefer framing as manageable problems rather than systemic dysfunction* |

**Source references:**

- Bipartisan Policy Center, "Advancing Health Innovation" (2023)
- Research!America bipartisan polling on science funding support
- Congressional testimony from centrist members on NIH appropriations

#### Solution Evaluations

| Solution | Score | Stated Position | Underlying Concerns |
|----------|-------|-----------------|---------------------|
| Longer, larger grants | 8/10 | *Support evidence-based reform that reduces waste and improves outcomes* | *Want pilot data before full implementation* |
| F&A cost reform | 7/10 | *Support transparency and gradual reform; cautious about disruptive caps* | *Prefer incremental approach to avoid institutional damage* |
| Diversifying funding portfolio | 7/10 | *Support expanded opportunity based on merit; cautious about rigid mandates* | *Want balance between equity and scientific excellence* |
| Clinical trial modernization | 9/10 | *Strong support for evidence-based modernization* | *Model bipartisan issue with broad benefits* |
| Reproducibility mandates | 8/10 | *Strong support; good governance and evidence-based standard* | *Consistent with pragmatic, evidence-driven approach* |
| Workforce reform | 7/10 | *Support reasonable improvements to compensation and transparency* | *Prefer market-informed rather than mandate-driven approaches* |

#### Legislation Evaluations

| Bill | Score | Stated Position | Underlying Concerns |
|------|-------|-----------------|---------------------|
| NIH Reform and Accountability Act | 7/10 | *Support most provisions; prefer phased implementation and pilot programs before mandates* | *Would soften F&A cap and make some provisions advisory* |
| Clinical Trial Modernization Act | 8/10 | *Strong support; model bipartisan legislation* | *Minor concerns about cost; prefer budget-neutral implementation* |

#### Alternative Proposals

- Bipartisan commission to recommend NIH structural reforms
- Phased pilot programs for all major reforms before nationwide mandates
- Public-private partnerships for translational research rather than government-only programs
- Incremental F&A transparency improvements without hard caps
- Voluntary diversity compacts between NIH and research institutions

#### Coalition Potential

- **Natural allies:** Liberal (on funding), Conservative (on accountability)
- **Potential bridges:** All perspectives; centrists naturally bridge between groups
- **Unlikely partners:** None consistently; may have difficulty with extreme positions from any direction

---

### Religious Right Perspective

#### Engagement Consistency Assessment

**Score: 3/5 - Mixed Consistency**

| Indicator | Assessment |
|-----------|------------|
| Stated vs actual motivations | Genuine moral and ethical concerns about specific research methods; broader positions influenced by coalition politics |
| Principle consistency | Consistent on bioethics issues; less consistent on general research policy |
| Goalpost stability | Stable on moral red lines (embryonic research, fetal tissue); variable on funding and reform |
| Zero-sum behavior | Moderate; bioethics issues can become litmus tests that override other considerations |

**Justification:** The Religious Right's engagement with biomedical research is shaped primarily by bioethics concerns, particularly regarding embryonic stem cell research, fetal tissue research, and emerging technologies that raise questions about human dignity (gene editing, human-animal chimeras). On these issues, positions are principled and deeply held. On broader research funding and reform questions, positions tend to follow conservative coalition dynamics rather than independent analysis.

**Evidence for assessment:**

- Consistent opposition to federal funding for embryonic stem cell research across multiple administrations
- George W. Bush's stem cell funding restrictions reflected Religious Right influence
- Family Research Council publications on bioethics and research policy
- Support for NIH funding when decoupled from objectionable research areas

#### Position Scores

| Dimension | Score | Reasoning |
|-----------|-------|-----------|
| Current State Assessment | 5/10 | *Generally accept factual analysis but frame priorities through moral lens; less concerned about workforce issues, more concerned about ethical boundaries* |
| Root Cause Agreement | 4/10 | *Limited engagement with structural analysis; primary concern is moral direction of research rather than funding mechanisms* |

**Source references:**

- Family Research Council, "Ethical Boundaries in Biomedical Research" (various)
- Charlotte Lozier Institute analyses of fetal tissue and embryonic research
- National Association of Evangelicals statements on science and ethics

#### Solution Evaluations

| Solution | Score | Stated Position | Underlying Concerns |
|----------|-------|-----------------|---------------------|
| Longer, larger grants | 5/10 | *Neutral unless grants fund ethically objectionable research* | *Ensure no expansion of embryonic or fetal tissue research* |
| F&A cost reform | 6/10 | *Support accountability as good stewardship* | *Align with general conservative fiscal concerns* |
| Diversifying funding portfolio | 4/10 | *Cautious about diversity mandates; support merit-based allocation* | *Follow conservative coalition on identity-based provisions* |
| Clinical trial modernization | 6/10 | *Support patient access; want ethical guardrails* | *Ensure informed consent reflects moral considerations* |
| Reproducibility mandates | 6/10 | *Support honesty and integrity in science* | *Ethical and faith-based commitment to truth* |
| Workforce reform | 4/10 | *Follow conservative position on wage mandates* | *Not a primary concern for this perspective* |

#### Legislation Evaluations

| Bill | Score | Stated Position | Underlying Concerns |
|------|-------|-----------------|---------------------|
| NIH Reform and Accountability Act | 5/10 | *Support accountability provisions; want explicit prohibition on ethically objectionable research expansion* | *Would add conscience protections and bioethics review requirements* |
| Clinical Trial Modernization Act | 5/10 | *Neutral to cautiously supportive; want ethical guardrails on research types covered* | *Ensure modernization does not expand morally objectionable research* |

#### Alternative Proposals

- Explicit prohibition on federal funding for embryonic stem cell research and human cloning
- Required bioethics review for all NIH-funded research involving human subjects or tissues
- Conscience protection for researchers who object to participating in ethically controversial research
- Expanded funding for adult stem cell and induced pluripotent stem cell research as ethical alternatives
- Faith-based health research partnerships

#### Coalition Potential

- **Natural allies:** Conservative (on general policy), Constitutionalist (on federal limits)
- **Potential bridges:** Centrist (on pragmatic reform), Liberal (on specific disease areas)
- **Unlikely partners:** Progressive (on bioethics framework), Democratic Socialist (on government role and values)

---

### Democratic Socialist Perspective

#### Engagement Consistency Assessment

**Score: 5/5 - Highly Consistent**

| Indicator | Assessment |
|-----------|------------|
| Stated vs actual motivations | Transparent about priorities: public investment, worker rights, democratic accountability, equitable access |
| Principle consistency | Same framework applied uniformly: public goods should serve the public, workers deserve fair treatment, corporations should not capture public investment |
| Goalpost stability | Very stable; positions clearly articulated and maintained |
| Zero-sum behavior | Low; focused on restructuring rather than blocking |

**Justification:** Democratic Socialists apply a consistent analytical framework to biomedical research: publicly funded research is a public good that should be democratically governed and universally accessible. Their positions on pricing, workforce, equity, and institutional reform follow directly from this framework and are applied consistently.

**Evidence for assessment:**

- Sanders/Warren pharmaceutical pricing proposals directly reference publicly funded research
- DSA health policy platform consistently links research funding to access and pricing
- Academic scholarship (Mazzucato, Baker) provides rigorous intellectual foundation
- Consistent advocacy for graduate student and postdoc unionization

#### Position Scores

| Dimension | Score | Reasoning |
|-----------|-------|-----------|
| Current State Assessment | 9/10 | *Strong agreement; would emphasize even more the role of corporate capture and labor exploitation* |
| Root Cause Agreement | 10/10 | *Full agreement with structural analysis; add corporate power and commodification of public goods as core causes* |

**Source references:**

- Sanders, Bernie. *It's OK to Be Angry About Capitalism*. 2023. (Includes sections on pharmaceutical industry and public research)
- Baker, Dean. "Rigged: How Globalization and the Rules of the Modern Economy Were Structured to Make the Rich Richer." 2016. (Analysis of IP and pharmaceutical pricing)
- DSA health policy platform and Medicare for All framework
- Mazzucato, Mariana. *The Value of Everything*. 2018.

#### Solution Evaluations

| Solution | Score | Stated Position | Underlying Concerns |
|----------|-------|-----------------|---------------------|
| Longer, larger grants | 7/10 | *Support stability for researchers; want to ensure equitable distribution* | *Concern that benefits flow to privileged institutions without equity provisions* |
| F&A cost reform | 10/10 | *Strongly support; university administrators should not profit from public research* | *View high overhead as administrative extraction* |
| Diversifying funding portfolio | 10/10 | *Central priority; mandatory redistribution and equity provisions essential* | *Structural equity is non-negotiable* |
| Clinical trial modernization | 8/10 | *Support access and diversity; insist on pricing conditions for resulting treatments* | *Modernization must serve patients, not industry profit* |
| Reproducibility mandates | 8/10 | *Support transparency and democratic accountability for public spending* | *Consistent with democratic governance of public goods* |
| Workforce reform | 10/10 | *Central priority; graduate students and postdocs are exploited workers deserving union rights and fair pay* | *Labor rights framework is foundational* |

#### Legislation Evaluations

| Bill | Score | Stated Position | Underlying Concerns |
|------|-------|-----------------|---------------------|
| NIH Reform and Accountability Act | 7/10 | *Good start but insufficient; need mandatory pricing conditions, stronger F&A caps, and union recognition* | *Would transform into more comprehensive public interest legislation* |
| Clinical Trial Modernization Act | 7/10 | *Support structure but need pricing conditions and stronger public return on investment provisions* | *Without pricing reform, modernization primarily benefits pharmaceutical companies* |

#### Alternative Proposals

- Public pharmaceutical development and manufacturing corporation
- Mandatory reasonable pricing for all drugs with significant public research investment
- Exercise Bayh-Dole march-in rights as standard practice
- Recognize collective bargaining rights for all NIH-funded trainees
- Create a National Health Research Service with salaried researchers (modeled on NHS research)
- F&A cap at 25% with full public accounting
- Free and immediate open access for all publicly funded research

#### Coalition Potential

- **Natural allies:** Progressive, Liberal (on funding, equity, workforce)
- **Potential bridges:** Populist (on drug pricing and anti-corporate measures)
- **Unlikely partners:** Conservative (on pricing and government role), Libertarian (on fundamental approach), Constitutionalist (on federal authority)

---

## Summary Tables

### Master Comparison

| Perspective | Consistency | Current State | Root Causes | Solutions Avg | Legislation Avg |
|-------------|-------------|---------------|-------------|---------------|-----------------|
| Conservative | 4/5 | 7/10 | 6/10 | 6.3/10 | 6.5/10 |
| Liberal | 4/5 | 9/10 | 8/10 | 8.0/10 | 8.5/10 |
| Progressive | 5/5 | 9/10 | 9/10 | 8.7/10 | 7.0/10 |
| Libertarian | 4/5 | 5/10 | 4/10 | 4.3/10 | 3.5/10 |
| Constitutionalist | 4/5 | 5/10 | 4/10 | 4.0/10 | 3.5/10 |
| Populist | 3/5 | 7/10 | 6/10 | 6.7/10 | 6.0/10 |
| Centrist | 5/5 | 8/10 | 7/10 | 7.7/10 | 7.5/10 |
| Religious Right | 3/5 | 5/10 | 4/10 | 5.2/10 | 5.0/10 |
| Democratic Socialist | 5/5 | 9/10 | 10/10 | 8.8/10 | 7.0/10 |

### Solution Support Matrix

| Solution | Con | Lib | Prog | Libt | Const | Pop | Cent | RelR | DemSoc |
|----------|-----|-----|------|------|-------|-----|------|------|--------|
| Longer, larger grants | 7 | 8 | 7 | 4 | 4 | 5 | 8 | 5 | 7 |
| F&A cost reform | 8 | 6 | 9 | 6 | 5 | 9 | 7 | 6 | 10 |
| Diversifying funding portfolio | 5 | 9 | 10 | 3 | 3 | 6 | 7 | 4 | 10 |
| Clinical trial modernization | 8 | 8 | 8 | 7 | 5 | 7 | 9 | 6 | 8 |
| Reproducibility mandates | 6 | 8 | 8 | 4 | 4 | 7 | 8 | 6 | 8 |
| Workforce reform | 4 | 9 | 10 | 2 | 3 | 6 | 7 | 4 | 10 |

### Legislation Support Matrix

| Bill | Con | Lib | Prog | Libt | Const | Pop | Cent | RelR | DemSoc |
|------|-----|-----|------|------|-------|-----|------|------|--------|
| NIH Reform and Accountability Act | 6 | 8 | 7 | 3 | 3 | 6 | 7 | 5 | 7 |
| Clinical Trial Modernization Act | 7 | 9 | 7 | 4 | 4 | 6 | 8 | 5 | 7 |

### Engagement Consistency Distribution

| Level | Count | Perspectives |
|-------|-------|--------------|
| 5 - Highly Consistent | 3 | *Progressive, Centrist, Democratic Socialist* |
| 4 - Mostly Consistent | 4 | *Conservative, Liberal, Libertarian, Constitutionalist* |
| 3 - Mixed Consistency | 2 | *Populist, Religious Right* |
| 2 - Low Consistency | 0 | *None* |
| 1 - Unpredictable | 0 | *None* |

**High Consistency Majority:** 7/9 perspectives rated 4 or above

### Common Ground Synthesis

This matrix identifies which reforms have potential cross-ideological support and which face structural opposition.

| Reform Category | Broad Support (5+) | Narrow Support (3-4) | Structural Opposition |
|-----------------|-------------------|---------------------|----------------------|
| Clinical trial modernization | Conservative, Liberal, Progressive, Populist, Centrist, Democratic Socialist, Religious Right, Libertarian | Constitutionalist | None |
| F&A cost transparency and reform | Conservative, Liberal, Progressive, Populist, Centrist, Democratic Socialist, Libertarian, Religious Right | Constitutionalist | None (but university lobby opposes) |
| Reproducibility mandates | Liberal, Progressive, Populist, Centrist, Democratic Socialist, Conservative, Religious Right | Libertarian, Constitutionalist | None |
| Longer, larger grants | Conservative, Liberal, Progressive, Centrist, Democratic Socialist | Populist, Religious Right | Libertarian, Constitutionalist |
| Workforce reform (pay, transparency) | Liberal, Progressive, Centrist, Democratic Socialist | Conservative, Populist, Religious Right | Libertarian, Constitutionalist |
| Diversifying funding portfolio | Liberal, Progressive, Centrist, Democratic Socialist, Populist | Conservative, Religious Right | Libertarian, Constitutionalist |
| Drug pricing conditions | Progressive, Democratic Socialist, Populist | Liberal, Centrist | Conservative, Libertarian, Constitutionalist |

**Key insight:** Clinical trial modernization and F&A reform have the broadest cross-ideological support and should be prioritized as entry points for bipartisan legislation. Workforce reform and funding diversification have strong support from the center-left coalition but face ideological opposition from limited-government perspectives. Drug pricing conditions are the most politically divisive element and should be pursued separately to avoid derailing broader reform.

---

## Compromise Proposals

### Compromise 1: *Bipartisan Research Accountability and Trial Modernization Package*

**Bridges:** Conservative + Liberal + Centrist + Populist

**Core Agreement:** All four perspectives agree that NIH funding should be spent more efficiently, that indirect costs should be transparent, and that clinical trials should be modernized to reach more patients faster.

**Policy Description:**

A combined package including F&A transparency requirements (without a hard cap), expanded clinical trial decentralization, community trial network, and reproducibility mandates. Excludes the most contentious elements: F&A cap, drug pricing conditions, workforce wage mandates, and diversity quotas.

**Concern Mapping:**

| Perspective | How This Addresses Their Concerns |
|-------------|-----------------------------------|
| Conservative | *Accountability and transparency without new mandates; deregulatory trial reforms; fiscal discipline* |
| Liberal | *Improved clinical trial access and diversity; reproducibility improvements; evidence-based policy* |
| Centrist | *Bipartisan, evidence-based, pragmatic approach; pilot programs before mandates* |
| Populist | *Taxpayer accountability; rural trial access; reduced elite institutional privilege* |

**Concessions:**

| Perspective | What They Give Up |
|-------------|-------------------|
| Conservative | *Accept some new spending on community trial network and reproducibility programs* |
| Liberal | *Defer F&A cap, drug pricing conditions, and binding diversity mandates to future legislation* |
| Centrist | *Accept slightly faster reform timeline than preferred incremental approach* |
| Populist | *Defer drug pricing reform to separate legislation* |

**Viability Assessment:**

- **Coalition Size:** 4/9 perspectives (but representing the political mainstream)
- **High Consistency Ratio:** 3/4 coalition members rated 4+ consistency
- **Durability:** *High; avoids most contentious issues while delivering meaningful reform*
- **Implementation Path:** *Bipartisan bill modeled on 21st Century Cures Act; committee markup through HELP and Energy & Commerce*

---

### Compromise 2: *Research Workforce Fairness and Transparency Act*

**Bridges:** Liberal + Progressive + Democratic Socialist + Centrist

**Core Agreement:** All four perspectives agree that the biomedical workforce pipeline is broken, that trainees deserve fair compensation, and that career outcome transparency is essential.

**Policy Description:**

Mandatory career outcome reporting for all NIH-funded training programs; postdoctoral salary floor of $65,000 (lower than the $70,000 in the main bill); graduate stipend floor of $38,000; creation of the Staff Scientist career track; and professional development requirements. Does not include training pipeline caps or union recognition mandates.

**Concern Mapping:**

| Perspective | How This Addresses Their Concerns |
|-------------|-----------------------------------|
| Liberal | *Fair wages, career transparency, and expanded career paths for researchers* |
| Progressive | *Worker protection, institutional accountability, reduced exploitation* |
| Democratic Socialist | *Improved labor conditions for research workers; transparency as democratic accountability* |
| Centrist | *Evidence-based workforce reform; moderate compensation increases; pilot programs* |

**Concessions:**

| Perspective | What They Give Up |
|-------------|-------------------|
| Liberal | *Accept lower salary floor than ideal; defer comprehensive diversity measures* |
| Progressive | *Defer mandatory union recognition and training pipeline caps* |
| Democratic Socialist | *Accept market-informed (rather than needs-based) wage setting; defer collective bargaining provisions* |
| Centrist | *Accept mandatory (rather than voluntary) compensation floors* |

**Viability Assessment:**

- **Coalition Size:** 4/9 perspectives (center-left coalition)
- **High Consistency Ratio:** 4/4 coalition members rated 4+ consistency
- **Durability:** *Moderate; strong coalition commitment but faces opposition from universities and fiscal conservatives*
- **Implementation Path:** *Attach to NIH reauthorization or appropriations legislation; build public support through researcher advocacy*

---

### Compromise 3: *Public Research Return-on-Investment Act*

**Bridges:** Progressive + Democratic Socialist + Populist + Liberal

**Core Agreement:** All four perspectives agree that the public deserves a fair return on taxpayer-funded research, particularly when discoveries lead to expensive drugs.

**Policy Description:**

Mandatory F&A cap at 45% (phased in over 7 years); transparency requirements for all licensing agreements involving publicly funded inventions; "reasonable access" provisions requiring that publicly funded discoveries be made available at reasonable terms; and enhanced NIH authority to exercise march-in rights under specific, defined conditions.

**Concern Mapping:**

| Perspective | How This Addresses Their Concerns |
|-------------|-----------------------------------|
| Progressive | *Structural reform of public-private research relationship; F&A cap reduces institutional extraction* |
| Democratic Socialist | *Public return on public investment; reduced corporate capture of public goods* |
| Populist | *Taxpayer accountability; reduced pharmaceutical profiteering; anti-elite reform* |
| Liberal | *Improved research efficiency; public access provisions; institutional accountability* |

**Concessions:**

| Perspective | What They Give Up |
|-------------|-------------------|
| Progressive | *Accept higher F&A cap (45% vs. preferred 30%); accept limited march-in conditions rather than routine exercise* |
| Democratic Socialist | *Defer public pharmaceutical manufacturing; accept market-based rather than administered pricing* |
| Populist | *Accept phased implementation rather than immediate caps; work within existing institutional framework* |
| Liberal | *Accept F&A cap despite university opposition; support march-in provisions despite industry concerns* |

**Viability Assessment:**

- **Coalition Size:** 4/9 perspectives (left-populist coalition)
- **High Consistency Ratio:** 3/4 coalition members rated 4+ consistency
- **Durability:** *Moderate; strong commitment from coalition members but faces intense opposition from universities and pharmaceutical industry*
- **Implementation Path:** *Requires strong public campaign; attach to popular drug pricing legislation; build on public anger over drug costs*

---

## Strategic Implications

### Most Viable Coalition

The **Bipartisan Research Accountability and Trial Modernization Package** (Compromise 1) represents the most politically viable reform pathway. It commands support from the political mainstream (Conservative, Liberal, Centrist, Populist), avoids the most contentious issues, and builds on the precedent of the 21st Century Cures Act. This should be the initial legislative vehicle.

### Key Obstacles

1. **University lobbying**: Research universities will resist F&A reform regardless of the coalition. Their political influence in key congressional districts makes this the single most difficult institutional barrier.
2. **Pharmaceutical industry**: Any provisions affecting IP, pricing, or technology transfer will trigger intense industry opposition. Separating these from the core bipartisan package is essential for initial progress.
3. **Political polarization**: While biomedical research has historically been bipartisan, post-COVID politicization of NIH and public health has reduced bipartisan goodwill. Rebuilding trust is a prerequisite for major reform.
4. **Inertia**: Academic culture changes slowly. Even well-designed policies may take a decade or more to shift incentive structures and behaviors.

### Low Consistency Partners

The **Populist** (3/5) and **Religious Right** (3/5) perspectives are the least predictable coalition partners. For populists, the key is framing reform in anti-elite, taxpayer-accountability terms rather than technocratic or equity language. For the Religious Right, the key is either engaging on shared bioethics concerns or ensuring that reform legislation does not expand morally objectionable research areas.

### Recommended Approach

1. **Lead with Compromise 1**: Pursue the bipartisan accountability and trial modernization package as the initial legislative vehicle. Demonstrate results and build political capital.
2. **Build workforce reform momentum**: Advance Compromise 2 through NIH administrative action (salary floors, career outcome reporting) while building support for legislation.
3. **Sequence pricing reform carefully**: Pursue Compromise 3 elements (F&A cap, pricing conditions) only after establishing the bipartisan reform foundation. Link to broader drug pricing reform efforts.
4. **Maintain bipartisan framing**: Emphasize taxpayer value, patient access, American competitiveness, and accountability. Avoid partisan language that triggers reflexive opposition.
5. **Engage patient advocates**: Disease advocacy organizations are the most politically powerful pro-reform constituency. Enlist their support for structural reform, not just disease-specific funding.

---

## Document Navigation

- Previous: [Legislation](11-legislation.md)
